Cargando…

Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

BACKGROUND: There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, Fredriksen, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547032/
https://www.ncbi.nlm.nih.gov/pubmed/34702245
http://dx.doi.org/10.1186/s12888-021-03522-6
_version_ 1784590306361999360
author Bigseth, Therese Torgersen
Engh, John Abel
Egeland, Jens
Andersen, Eivind
Andreassen, Ole Andreas
Bang-Kittilsen, Gry
Falk, Ragnhild Sørum
Holmen, Tom Langerud
Lindberg, Morten
Mordal, Jon
Nielsen, Jimmi
Steen, Nils Eiel
Ueland, Thor
Vang, Torkel
Fredriksen, Mats
author_facet Bigseth, Therese Torgersen
Engh, John Abel
Egeland, Jens
Andersen, Eivind
Andreassen, Ole Andreas
Bang-Kittilsen, Gry
Falk, Ragnhild Sørum
Holmen, Tom Langerud
Lindberg, Morten
Mordal, Jon
Nielsen, Jimmi
Steen, Nils Eiel
Ueland, Thor
Vang, Torkel
Fredriksen, Mats
author_sort Bigseth, Therese Torgersen
collection PubMed
description BACKGROUND: There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. METHOD: In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. RESULTS: Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. CONCLUSION: Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-021-03522-6.
format Online
Article
Text
id pubmed-8547032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85470322021-10-26 Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms Bigseth, Therese Torgersen Engh, John Abel Egeland, Jens Andersen, Eivind Andreassen, Ole Andreas Bang-Kittilsen, Gry Falk, Ragnhild Sørum Holmen, Tom Langerud Lindberg, Morten Mordal, Jon Nielsen, Jimmi Steen, Nils Eiel Ueland, Thor Vang, Torkel Fredriksen, Mats BMC Psychiatry Research BACKGROUND: There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. METHOD: In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. RESULTS: Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. CONCLUSION: Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-021-03522-6. BioMed Central 2021-10-26 /pmc/articles/PMC8547032/ /pubmed/34702245 http://dx.doi.org/10.1186/s12888-021-03522-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bigseth, Therese Torgersen
Engh, John Abel
Egeland, Jens
Andersen, Eivind
Andreassen, Ole Andreas
Bang-Kittilsen, Gry
Falk, Ragnhild Sørum
Holmen, Tom Langerud
Lindberg, Morten
Mordal, Jon
Nielsen, Jimmi
Steen, Nils Eiel
Ueland, Thor
Vang, Torkel
Fredriksen, Mats
Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
title Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
title_full Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
title_fullStr Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
title_full_unstemmed Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
title_short Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
title_sort exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547032/
https://www.ncbi.nlm.nih.gov/pubmed/34702245
http://dx.doi.org/10.1186/s12888-021-03522-6
work_keys_str_mv AT bigseththeresetorgersen exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT enghjohnabel exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT egelandjens exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT anderseneivind exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT andreassenoleandreas exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT bangkittilsengry exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT falkragnhildsørum exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT holmentomlangerud exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT lindbergmorten exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT mordaljon exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT nielsenjimmi exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT steennilseiel exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT uelandthor exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT vangtorkel exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms
AT fredriksenmats exploringlowgradeinflammationbysolubleurokinaseplasminogenactivatorreceptorlevelsinschizophreniaasexdependentassociationwithdepressivesymptoms